Merck - 15 Year Stock Price History | MRK
Historical daily share price chart and data for Merck since 2011 adjusted for splits and dividends. The latest closing stock price for Merck as of September 04, 2026 is 150.33.
- The all-time high Merck stock closing price was 156.45 on August 25, 2026.
- The Merck 52-week high stock price is 156.92, which is 4.4% above the current share price.
- The Merck 52-week low stock price is 77.58, which is 48.4% below the current share price.
- The average Merck stock price for the last 52 weeks is 111.70.
| Merck Historical Annual Stock Price Data | ||||||
|---|---|---|---|---|---|---|
| Year | Average Stock Price | Year Open | Year High | Year Low | Year Close | Annual % Change |
| 2026 | 120.6384 | 104.9130 | 156.4500 | 104.9130 | 150.3300 | 44.91% |
| 2025 | 84.1989 | 94.1968 | 105.2380 | 70.3885 | 103.7400 | 9.79% |
| 2024 | 110.5885 | 104.7030 | 124.4570 | 90.7537 | 94.4912 | -6.26% |
| 2023 | 98.4950 | 99.9646 | 107.2170 | 91.9620 | 100.8010 | 1.01% |
| 2022 | 79.4526 | 66.9872 | 100.8460 | 64.0591 | 99.7937 | 49.42% |
| 2021 | 64.8963 | 64.9609 | 78.1582 | 57.9080 | 66.7867 | 1.75% |
| 2020 | 63.7536 | 71.5786 | 71.5786 | 52.0653 | 65.6349 | -7.20% |
| 2019 | 62.9894 | 57.2267 | 71.3454 | 55.2054 | 70.7309 | 22.27% |
| 2018 | 47.8145 | 41.2965 | 59.6476 | 39.4455 | 57.8475 | 39.95% |
| 2017 | 44.9113 | 42.8692 | 48.1881 | 39.4041 | 41.3332 | -1.49% |
| 2016 | 40.2862 | 36.2324 | 45.9447 | 33.5467 | 41.9570 | 15.05% |
| 2015 | 38.3420 | 38.2096 | 42.1113 | 33.1429 | 36.4671 | -3.89% |
| 2014 | 37.5883 | 32.0852 | 41.0329 | 32.0852 | 37.9423 | 16.93% |
| 2013 | 29.4833 | 25.8347 | 32.4482 | 25.5284 | 32.4482 | 26.83% |
| 2012 | 25.2358 | 22.9739 | 29.6870 | 22.3800 | 25.5847 | 13.14% |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | Large Cap Pharmaceutical | $370.890B | $65.011B |
| Merck & Co. boasts more than six blockbuster drugs in its portfolio with PD-L1 inhibitor, Keytruda, approved for several types of cancer. Keytruda has played an instrumental role in driving Merck's steady revenue growth in the past few years. Well-known products in Merck's portfolio include Keytruda, Simponi , Januvia and Janumet, Bridion, Isentress, ProQuad, Gardasil, Pneumovax 23, RotaTeq and Belsomra. Merck made its biggest acquisition of Schering-Plough and sold off its Consumer Care business to Bayer. Other key acquisitions include Idenix Pharmaceuticals, Cubist Pharmaceuticals, Rigontec, ArQule and Acceleron Pharma. IMerck spun off products from its Women's Health unit, legacy drugs and biosimilar products into a new publicly traded company called Organon & Co. | |||
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Eli Lilly (LLY) | United States | $1081.958B | 36.50 |
| Johnson & Johnson (JNJ) | United States | $663.276B | 25.34 |
| AbbVie (ABBV) | United States | $453.112B | 23.59 |
| Roche Holding AG (RHHBY) | Switzerland | $350.157B | 0.00 |
| Novartis AG (NVS) | Switzerland | $305.285B | 18.43 |
| Novo Nordisk (NVO) | Denmark | $208.069B | 11.59 |
| Pfizer (PFE) | United States | $162.156B | 9.33 |
| Sanofi (SNY) | France | $107.257B | 9.03 |
| Bayer (BAYRY) | Germany | $55.767B | 9.92 |
| Innoviva (INVA) | United States | $1.541B | 5.27 |